Efficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction

May 9, 2026 updated by: Ali Mohamed Ali ismail, Cairo University
females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism) will be divided to groups (twenty female for the group). groups will be treated with levothyroxine and metformin, but one of these groups will perform aerobic treadmill walking.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Egypt
      • Giza, Egypt
        • Recruiting
        • Cairo Unoversity
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • PCOS
  • fattty pancrease (non-alcoholic)
  • subclinical hypothyroid (signifcant with thyroid stimauted horomone more than 10 mIU/L) and normal non-disordered free thyroxine horomones

Exclusion Criteria:

  • cardiac disesase
  • renal diseases
  • respiratory disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group number 1
twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin, and these females will perform 50 minutes of aerobic treadmill walking hrice weekly for six month.
Behavioral: physical exercise program
twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin, and these females will perform 50 minutes of aerobic treadmill walking hrice weekly for six month.
Active Comparator: group number 2
twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin for six month
Other: usual care
twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily two times of 500-mg metformin for six month.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dehydroepiandrosterone
Time Frame: it will be measured after 6 months
it is a hormone involved in synthesis of sex hormones
it will be measured after 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ratio of leutinzing hromone to hormone of follicels stimulatting hormones
Time Frame: it will be measured after 6 months
this ration express level of sex hormone
it will be measured after 6 months
testesterone
Time Frame: it will be measured after 6 months
it is a sex horomone
it will be measured after 6 months
body mass index
Time Frame: it will be measured after 6 months
it will be assessed on empty stomach and bladder
it will be measured after 6 months
waist circumference
Time Frame: it will be measured after 6 months
it will be assessed on umblical levels
it will be measured after 6 months
blood gluocose
Time Frame: it will be measured after 6 months
it will be assessed in fasting status
it will be measured after 6 months
glycated hemoglubin
Time Frame: it will be measured after 6 months
it is an indiactor for longterm satus of blood gloucose
it will be measured after 6 months
insulin
Time Frame: it will be measured after 6 months
it will be assessed in plasma
it will be measured after 6 months
thyroid stimualtined horomone
Time Frame: it will be measured after 6 months
it will be assessed in plasma
it will be measured after 6 months
triglyceridess
Time Frame: it will be measured after 6 months
it will be assessed in plasma
it will be measured after 6 months
low densitiy liopporotein
Time Frame: it will be measured after 6 months
it will be assessed in plasma
it will be measured after 6 months
cholesteroll
Time Frame: it will be measured after 6 months
it will be assessed in plasma
it will be measured after 6 months
high densitiy lipoporteins
Time Frame: it will be measured after 6 months
it will be assessed in plasma
it will be measured after 6 months
alanine transaminase
Time Frame: it will be measured after 6 months
it will be assessed in plasma
it will be measured after 6 months
aspartatte transaminase
Time Frame: it will be measured after 6 months
it will be assessed in plasma
it will be measured after 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Investigators

  • Principal Investigator: Ali MA Ismail, lecturer, Cairo university

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 7, 2026

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

December 30, 2026

Study Registration Dates

First Submitted

May 9, 2026

First Submitted That Met QC Criteria

May 9, 2026

First Posted (Actual)

May 15, 2026

Study Record Updates

Last Update Posted (Actual)

May 15, 2026

Last Update Submitted That Met QC Criteria

May 9, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB000-14233-74

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Polycystic Ovary Syndrome

Clinical Trials on physical exercise program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe